Endo International

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products,.

NEW YORK, June 15, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Endo International plc ("Endo" or the "Company") (NASDAQ: ENDP). Investors who purchased Endo securities are encouraged to obtain...

ENDP Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Endo International plc and Encourages Investors to Contact the Firm

Mylan

TherapeuticsMD

Have extra cash to spare? These drug stocks are significantly undervalued and could make you wealthy in the long run.

3 Drug Stocks That Could Soar in 2020

Endo (ENDP) reported earnings 30 days ago. What's next for the stock?

Endo (ENDP) Up 1.7% Since Last Earnings Report: Can It Continue?

DUBLIN, May 14, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020 at 9:10 a.m. ET. A live webcast and...

Endo to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference

DUBLIN, May 14, 2020 /PRNewswire/ -- Endo International plc (the "Company") (NASDAQ:ENDP) announced today that its wholly owned subsidiaries, Par Pharmaceutical, Inc., a New York corporation ("PPI"), Endo Designated Activity Company, a designated activity company incorporated under the...

Endo International plc Announces Proposed Exchange Offers And Consent Solicitations

Endo's (ENDP) earnings and sales beat estimates in the first quarter owing to increased customer inventory purchasing due to the COVID-19 pandemic

Endo (ENDP) Q1 Earnings Beat on Coronavirus-Led Stockpiling

The drugmaker easily beat revenue and earnings estimates with a big jump in sterile injectables sales.

Endo International Fires on All Cylinders in Q1 Thanks to COVID-19 Impact

Endo International plc's (ENDP) CEO Blaise Coleman on Q1 2020 Results - Earnings Call Transcript

Shares of Endo International (NASDAQ:ENDP) rose 1.1% after the company reported Q1 results.

Endo International: Q1 Earnings Insights

Endo (ENDP) delivered earnings and revenue surprises of 75.93% and 14.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Endo International (ENDP) Q1 Earnings and Revenues Top Estimates

A billion-dollar market opportunity exists for an opioid manufacturer plagued with lawsuits, but will it be enough for a comeback?

Will an Opioid Manufacturer Stage a Comeback With This New Venture?

Why Endo International Is A Good Trade

Why Is Endo (ENDP) Down 33% Since Last Earnings Report?

Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

Implied Volatility Surging for Endo International (ENDP) Stock Options

Endo (ENDP) earnings and sales beat estimates in the fourth quarter but witness year-over-year declines.

Endo's (ENDP) Earnings & Revenues Trump Estimates in Q4

Endo International plc (ENDP) CEO Paul Campanelli on Q4 2019 Results - Earnings Call Transcript

Endo (ENDP) delivered earnings and revenue surprises of 29.82% and 5.25%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Endo International (ENDP) Q4 Earnings and Revenues Top Estimates

Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Endo International (ENDP) Q4 Earnings Expected to Decline

Community Health Systems

Cytokinetics

Momenta Pharmaceuticals

Owens & Minor

The small-cap healthcare companies are benefiting from the 2020 presidential election campaign, which has put pressure on the large cap cousins on how to overhaul the industry.

Small-Cap Healthcare ETF Outperforming in 2020: 5 Top Stocks

Mallinckrodt PLC

SmileDirectClub

These stocks skyrocketed during healthcare's biggest event of the year -- the J.P. Morgan Healthcare Conference.

3 Big Winners From the "Super Bowl of Healthcare"

Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.

Endo Up on Opioid Abuse Settlement Agreement With Oklahoma

Shares of Endo International Inc. are up 3% in afternoon trading on Friday after the company said it will pay $8.75 million to Oklahoma to settle allegations that it inappropriately promoted its opioids.

Endo settles opioid suit with Oklahoma AG

Avid Bioservices

IGM Biosciences Inc

Illumina

IVERIC bio Inc

Kodiak Sciences Inc

Neovasc

Pacira Pharmaceuticals

Pfizer

X4 Pharmaceuticals Inc

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfolio.

11 Biotechs and Pharma Stocks Being Given Huge Upside Targets for 2020

Why Is Endo (ENDP) Up 12.3% Since Last Earnings Report?

Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

News for Endo International Stock (ENDP)